| Title | Claps | Level | Year | L/Y |
|---|---|---|---|---|
|
Safety and activity of anti‐CD14 antibody IC14 (atibuclimab) in ALS: Experience with expanded access protocol
34 auth. D. Gelevski, Grace Addy, M. Rohrer, Caroline Cohen, Aimee Roderick, Allison Winter, Judith Carey, J. Scalia, M. Yerton, Harli Weber, Michael Doyle, Neil Parikh, Geli Kane, A. Ellrodt, Katherine M. Burke, ...
IC14 (atibuclimab) is a monoclonal anti‐CD14 antibody. A previous phase 1 trial of 10 participants with amyotrophic lateral sclerosis (ALS) demonstrated initial safety of IC14 in an acute treatment setting. We provided long‐term treatment with IC14 …
IC14 (atibuclimab) is a monoclonal anti‐CD14 antibody. A previous phase 1 trial of 10 participants with amyotrophic lateral sclerosis (ALS) demonstrated initial safety of IC14 in an acute treatment setting. We provided long‐term treatment with IC14 to individuals with ALS via an expanded access protocol (EAP) and documented target engagement, biomarker, safety, and disease endpoints.
Published in
Muscle and Nerve
|
2
|
2 | 2022 |
Social Media Posts